Issue 32, 2018

New Ru(ii) photocages operative with near-IR light: new platform for drug delivery in the PDT window

Abstract

A series of Ru(II) complexes bearing the tridentate 2,6-di(quinolin-2-yl)pyridine (dqpy) ligand were designed to undergo photoinduced ligand dissociation with red/near-IR light. The complexes [Ru(dqpy)(L)(CH3CN)]2+, where L = 2,2′-bipyridine (bpy, 1), 4,4′dimethyl-2,2′-bipyridine (Me2bpy, 2), and 1,10-phenanthroline (phen, 3). Complexes 1–3 exhibit red-shifted lowest energy metal-to-ligand charge transfer (MLCT) absorption maxima at ∼600 nm, as compared to the corresponding tpy (2,2′;6′,2′′-terpyridine) complexes with MLCT bands at ∼565 nm which appear as shoulders to the MLCT bands at ∼455 nm. This shift is attributed to the lower energy LUMO afforded by the dqpy ligand when compared to tpy, as evidenced by the shift of the first reduction wave to ∼0.3 V more positive potentials in the former. In addition, the lowest MLCT maximum of [Ru(dqpy)(acac)(CH3CN)]+ (4; acac = acetylacetonate) is observed at 770 nm, attributed to the additional increase in energy of the HOMO afforded by the presence of the π-donating acac ligand and supported by calculations. Complexes 1–3 undergo ligand substitution upon irradiation with red light, λirr ≥ 610 nm, and the ligand substitution photochemistry of 4 is accessible with near-IR light, λirr ≥ 715 nm and λirr = 735 nm. Complexes 1–4 exhibit similar quantum yields of ligand exchange, ΦL, with 450 and 600 nm irradiation, however, that of 4 is 2–3 times greater than those measured for 1–3. This enhancement is explained by the difference in ligand contributions to the HOMO. Density functional theory calculations predict partial dqpy ππ* character in the MLCT states of 1–3 and a mixed Ru/acac → dqpy metal/ligand-to-ligand charge transfer (ML-LCT) state in 4. The photoreactivity of 1–4 with tissue-penetrating red and near-IR light, together with their exceptional dark stability (>48 h), makes the new Ru(II)-dqpy platform ideal for the development of new complexes for photoinduced drug release and for other applications that require broad absorption from the ultraviolet and visible ranges into the near-IR, such as solar energy conversion.

Graphical abstract: New Ru(ii) photocages operative with near-IR light: new platform for drug delivery in the PDT window

Supplementary files

Article information

Article type
Edge Article
Submitted
10 May 2018
Accepted
04 Jul 2018
First published
20 Jul 2018
This article is Open Access

All publication charges for this article have been paid for by the Royal Society of Chemistry
Creative Commons BY-NC license

Chem. Sci., 2018,9, 6711-6720

New Ru(II) photocages operative with near-IR light: new platform for drug delivery in the PDT window

M. H. Al-Afyouni, T. N. Rohrabaugh, K. F. Al-Afyouni and C. Turro, Chem. Sci., 2018, 9, 6711 DOI: 10.1039/C8SC02094A

This article is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported Licence. You can use material from this article in other publications, without requesting further permission from the RSC, provided that the correct acknowledgement is given and it is not used for commercial purposes.

To request permission to reproduce material from this article in a commercial publication, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party commercial publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements